UNLABELLED: Many genes undergo aberrant methylation in human cancers, and microarray platforms enable more comprehensive profiling of aberrant DNA methylation patterns. RESULTS: 1,010 of 87,922 probes on the 88 K promoter array (606 genes) had a higher signal (log(2) > 2) in the pancreatic cancer line, Panc-1 compared to the non-neoplastic pancreatic duct line, HPDE. Using this cut-off, bisulfite sequencing and/or MSP confirmed differential methylation of all 27 genes (66 probes) predicted to be methylated by the MCA array. More than 1/2 of the genes aberrantly hypermethylated in Panc-1 were not expressed in the pancreatic duct (HPDE) by expression array analysis. Using the 244 K CpG island array, 1,968 CpG islands were differentially methylated in MiaPaca2 compared to normal pancreas. The MCA method was more likely to identify hypermethylation within CpG islands than a cocktail of methylation sensitive restriction enzymes. DNA methylation profiles using 10 ng of DNA were highly correlated with those obtained using 5 ug of DNA (R2 = 0.98). Analysis of 57 pancreatic cancers and 34 normal pancreata using MSP identified MDFI, hsa-miR-9-1, ZNF415, CNTNAP2 and ELOVL4 as methylated in 96%, 89%, 86%, 82% and 68% of the cancers vs. 9%, 15%, 6%, 3% and 97% of normal pancreata, respectively. METHODS: We used methylated CpG island amplification (MCA) and Agilent promoter and CpG island microarrays to identify differential DNA methylation patterns in pancreatic cancer vs. normal pancreas. We examined MCA array reproducibility, compared it to methylation profiles obtained using a cocktail of methylation-sensitive restriction enzymes and examined gene expression of methylated genes. CONCLUSION: Promoter and CpG island array analysis finds aberrant methylation of hundreds of promoters and CpG islands in pancreatic cancer cells.
UNLABELLED: Many genes undergo aberrant methylation in humancancers, and microarray platforms enable more comprehensive profiling of aberrant DNA methylation patterns. RESULTS: 1,010 of 87,922 probes on the 88 K promoter array (606 genes) had a higher signal (log(2) > 2) in the pancreatic cancer line, Panc-1 compared to the non-neoplastic pancreatic duct line, HPDE. Using this cut-off, bisulfite sequencing and/or MSP confirmed differential methylation of all 27 genes (66 probes) predicted to be methylated by the MCA array. More than 1/2 of the genes aberrantly hypermethylated in Panc-1 were not expressed in the pancreatic duct (HPDE) by expression array analysis. Using the 244 K CpG island array, 1,968 CpG islands were differentially methylated in MiaPaca2 compared to normal pancreas. The MCA method was more likely to identify hypermethylation within CpG islands than a cocktail of methylation sensitive restriction enzymes. DNA methylation profiles using 10 ng of DNA were highly correlated with those obtained using 5 ug of DNA (R2 = 0.98). Analysis of 57 pancreatic cancers and 34 normal pancreata using MSP identified MDFI, hsa-miR-9-1, ZNF415, CNTNAP2 and ELOVL4 as methylated in 96%, 89%, 86%, 82% and 68% of the cancers vs. 9%, 15%, 6%, 3% and 97% of normal pancreata, respectively. METHODS: We used methylated CpG island amplification (MCA) and Agilent promoter and CpG island microarrays to identify differential DNA methylation patterns in pancreatic cancer vs. normal pancreas. We examined MCA array reproducibility, compared it to methylation profiles obtained using a cocktail of methylation-sensitive restriction enzymes and examined gene expression of methylated genes. CONCLUSION: Promoter and CpG island array analysis finds aberrant methylation of hundreds of promoters and CpG islands in pancreatic cancer cells.
Authors: Hiromu Suzuki; Edward Gabrielson; Wei Chen; Ramaswamy Anbazhagan; Manon van Engeland; Matty P Weijenberg; James G Herman; Stephen B Baylin Journal: Nat Genet Date: 2002-05-06 Impact factor: 38.330
Authors: Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins Journal: Cancer Biol Ther Date: 2003 Jan-Feb Impact factor: 4.742
Authors: Noriyoshi Fukushima; Norihiro Sato; Takashi Ueki; Christophe Rosty; Kimberly M Walter; Robb E Wilentz; Charles J Yeo; Ralph H Hruban; Michael Goggins Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Norihiro Sato; Noriyoshi Fukushima; Anirban Maitra; Hiroyuki Matsubayashi; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Norihiro Sato; Takashi Ueki; Noriyoshi Fukushima; Christine A Iacobuzio-Donahue; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins Journal: Gastroenterology Date: 2002-07 Impact factor: 22.682
Authors: Norihiro Sato; Anirban Maitra; Noriyoshi Fukushima; N Tjarda van Heek; Hiroyuki Matsubayashi; Christine A Iacobuzio-Donahue; Christophe Rosty; Michael Goggins Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Noriyuki Omura; Margaret Griffith; Audrey Vincent; Ang Li; Seung-Mo Hong; Kimberly Walter; Michael Borges; Michael Goggins Journal: Mol Cancer Res Date: 2010-06-08 Impact factor: 5.852
Authors: Roberto A Lleras; Leslie R Adrien; Richard V Smith; Benjamin Brown; Naheed Jivraj; Christopher Keller; Cathy Sarta; Nicolas F Schlecht; Thomas M Harris; Geoffrey Childs; Michael B Prystowsky; Thomas J Belbin Journal: Am J Pathol Date: 2011-05 Impact factor: 4.307
Authors: Tatsuo Hata; Marco Dal Molin; Seung-Mo Hong; Koji Tamura; Masaya Suenaga; Jun Yu; Hiraku Sedogawa; Matthew J Weiss; Christopher L Wolfgang; Anne Marie Lennon; Ralph H Hruban; Michael G Goggins Journal: Clin Cancer Res Date: 2017-02-01 Impact factor: 12.531